Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5531337 | 0.83 | USP2 (0.38) | USP2ALDH1A1POLBGPR119HSP90AA1 | |
| SCHEMBL2576275 | 0.82 | ADORA1 (0.46) | USP2ALDH1A1POLBHSP90AA1MAPT | |
| SCHEMBL22481977 | 0.82 | USP2 (0.42) | USP2ALDH1A1POLBHSP90AA1MAPT | |
| SCHEMBL22615316 | 0.80 | SMN1; SMN2 (0.55) | USP2ALDH1A1POLBUSP30HSP90AA1 | |
| SCHEMBL22615425 | 0.79 | HSP90AA1 (0.37) | USP2ALDH1A1POLBUSP30HSP90AA1 | |
| SCHEMBL22621730 | 0.79 | HSP90AA1 (0.43) | USP2ALDH1A1POLBHSP90AA1 | |
| SCHEMBL3441391 | 0.78 | KMT2A (0.57) | USP2ALDH1A1POLBHSP90AA1MAPT | |
| SCHEMBL2587065 | 0.77 | KDM4E (0.47) | USP2ALDH1A1POLBHSP90AA1 | |
| SCHEMBL2582147 | 0.77 | HSP90AA1 (0.58) | USP2ALDH1A1POLBHSP90AA1MAPT | |
| SCHEMBL16217172 | 0.77 | ESR2 (0.43) | USP2ALDH1A1POLBGPR119HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306647-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITUS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-09-29 | — | — | US | disclosed |
| EP-3962914-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020221826-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2020-11-05 | — | — | WO | disclosed |
| US-8048879-B2 | Substituted 4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine compounds and use thereof for producing medicaments | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | P2RX5, P2RX4, P2RX7 | USP2 3751/4885ALDH1A1 1107/4885POLB 4291/4885 |
| US-20220306647-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITUS B VIRUS (HBV) | HCCS, IDO1, BRD4 | USP2 416/4885ALDH1A1 3923/4885POLB 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.